Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials

INTRODUCTION: Treatment selection in patients with advanced non-small cell lung cancer (NSCLC) is based on programmed death-ligand 1 (PD-L1) expression, which is usually scored manually and is subject to intra-/inter-pathologist variability. A PD-L1 clone-agnostic artificial intelligence (AI) model for AI-based measurement of PD-L1 (AIM-PD-L1) was developed and assessed in advanced NSCLC using clinical samples from two Phase 3 trials. METHODS: IMpower110 evaluated atezolizumab versus chemotherapy in PD-L1-positive metastatic, stage IV, squamous/nonsquamous NSCLC. IMpower150 evaluated atezolizumab, carboplatin and paclitaxel, with/without bevacizumab versus carboplatin, paclitaxel, and bevacizumab in patients with metastatic nonsquamous NSCLC. AIM-PD-L1 was developed and deployed on SP263-stained whole slide images (IMpower110, n=509; IMpower150, n=766) for digital scoring of tumor cell (TC) PD-L1 expression and identification of human interpretable features (HIFs) associated with survival outcomes. RESULTS: Overall percentage agreements between scoring methods for TC

• Herbst, R. S.
• Prizant, H.
• Ruderman, D.
• Conway, J.
• Shamshoian, J.
• Koeppen, H.
• Zou, W.
• de Marinis, F.
• Giaccone, G.
• Jassem, J.
• Spigel, D. R.
• Socinski, M. A.
• Reck, M.
• Molinero, L.
• Ballinger, M.
• Shames, D.
• Griffin, M.
• Yu, L.
• Agrawal, N.
• Beck, A.
• Wapinski, I.
• Hennek, S.
• Giltnane, J.
• Srivastava, M. K.